WA-TASSO
19.9.2023 14:01:33 CEST | Business Wire | Press release
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.
The Tasso+ device received Class II 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2022. With the CE Mark certification, Tasso+ now has achieved full clearance in the U.S. and the EU, making it the first device of its kind to do so.
“This designation is an important milestone for Tasso, allowing us to build upon the success of our CE Marked Tasso-M20 device and continue to expand our commercial footprint and reduce healthcare access barriers in Europe, where demand increasingly grows for patient-centric solutions,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “The Tasso+ CE Mark enables us to support the pharmaceutical industry, academic and government institutions on research and clinical initiatives, as well as accelerate access to remote testing and care for more patient populations. We are excited to expand our customer base in Europe.”
The Tasso+ device is a single-use blood lancing device for obtaining microliter capillary whole blood samples. Based on groundbreaking technology, Tasso+ allows for virtually painless blood samples to be collected remotely, with a user-friendly interface that boosts satisfaction and engagement.
The device can be used with compatible collection tubes to accelerate decentralized clinical trials for pharmaceutical companies, especially for pharmacokinetic and biomarker research endpoints. With a patient-centric collection process that overcomes care access barriers, Tasso+ enables underserved and understudied patient populations to participate in clinical trials. In addition, healthcare systems and physicians can use the Tasso+ device to make determinations on blood chemistries for their patients and expand access to care.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919146119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Announces First Quarter 2026 Financial Results14.5.2026 12:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its financial results for the three months ended March 31, 2026. First Quarter 2026 Highlights Total revenues were $43 million, representing a 9% year-over-year decrease. Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease. Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense to income from operations was $18 million, representing a
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 202614.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of
FPT Strengthens Bavarian Presence with New Munich Office, Accelerating AI Transformation14.5.2026 11:13:00 CEST | Press release
Global technology corporation FPT officially cut the ribbon on its latest office in Germany. This milestone reinforces the company's long-term commitment to delivering AI-driven services to its growing customer base across Germany and the wider European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514689341/en/ The inauguration ceremony was attended by H.E. Mr Nguyen Dac Thanh, Ambassador of Vietnam to Germany, alongside representatives from the local government, FPT executives, and key partners. Situated in one of Europe’s most dynamic technological and manufacturing hubs, the Munich office strengthens FPT’s delivery capabilities and enables faster, more scalable engagement across the region. The move underscores the company’s strategic focus on investing in key innovation hubs to meet rising demand for AI transformation and accelerate time-to-value for clients. "Our expanded presence in Munich allows us to sta
Reply Launches Model Factory, the Production Line for Creating Industrial-Grade Generative AI Models14.5.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] announces Reply Model Factory, an industrial production line for buildingfrontier generative AI modelsgrounded in corporate knowledge and designed to power AI systems and agents aligned with each organisation’s operational context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514524231/en/ Reply Model Factory is an industrial production line for building frontier generative AI models grounded in corporate knowledge and designed to power AI systems and agents aligned with each organisation’s operational context. AI models are often built to operate across a wide range of tasks, drawing largely on public data. Enterprises, however, rely on internal knowledge: technical standards, regulatory requirements, operating procedures, proprietary systems and domain expertise. Reply Model Factory addresses this gap by enabling organisations to train models that understand their own context and operate consist
Stitch Raises $25M Series A Led by Andreessen Horowitz14.5.2026 09:00:00 CEST | Press release
In a16z’s first investment in the GCC, the Riyadh-based fintech positions itself as the unified infrastructure layer for financial institutions worldwide Stitch, the operating system built for modern financial institutions, today announced it has raised $25 million in Series A funding led by Andreessen Horowitz (a16z). The investment marks a16z’s first in the GCC and brings Stitch’s total funding to $35 million. In addition to a16z, existing investors Arbor Ventures, COTU Ventures, Raed Ventures, and SVC also participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514070694/en/ Mohamed Oueida - Founder & CEO, Stitch (Photo: AETOSWire) Despite spending over $1 trillion on digital transformation in the last three years, most financial institutions are still running on the same fragmented, legacy infrastructure that has defined the sector for decades. Globally, banks spend $700 billion a year on technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom